Ankit Samanta, Subrata Ghosh, Sabyasachi Sarkar.Nanodrugs Targeting T Cells in Tumor Therapy. Sustained generation of peroxide from the air by carbon nano onion under visible light to combat RNA virus. Bikram Gurung, Sajan Pradhan, Debesh Sharma, Deshaj Bhujel, Siddhant Basel, Shivanand Chettri, Sagarmani Rasaily, Anand Pariyar, Sudarsan Tamang.An electrochemical strategy for synthesising carbon-based nanomaterials with tuned redox properties. Published by Oxford University Press on behalf of the British Society for Immunology.Zhenzhen Wang, Jiangjiexing Wu, Jia-Jia Zheng, Xiaomei Shen, Liang Yan, Hui Wei, Xingfa Gao, Yuliang Zhao.Perovskite quantum dots as a visible light photocatalyst for cyclisation of diamines and amino alcohols: an efficient approach to synthesize imidazolidines, fused-imidazolidines and oxazolidines. RNA sequencing analyses identified new pathways regulated by TRPV2, and also by the combination treatment.Īutoimmunity ion channels rheumatoid arthritis rodent models. In conclusion, the TRPV2 agonist achieved an overall similar reduction in arthritis severity and histology scores as etanercept, but the combination therapy achieved a more sustained disease control and more pronounced reduction in joint damage, suggesting a potential future option for improving disease control in RA. The combination therapy affected additional pathways not seen in the monotherapy groups. RNA sequencing and pathway analyses of synovial tissues identified pathways and processes regulated by the TRPV2 agonist, such as chemotaxis and cytokine receptor signaling, including IL6R.
All treatment groups had reduced scores for synovial inflammation, synovial hyperplasia and erosive changes, compared with controls, with the combination group achieving the most significant protection. The combination therapy group achieved a more robust and sustained reduction in disease severity than either monotherapy group. The O1821 protection was observed at an earlier time-point than in the etanercept group. Mice on monotherapy with either O1821 or etanercept developed milder clinical disease. Synovial tissues were obtained for RNA sequencing.
Following the onset of CIA DBA1/j mice were started on treatment with either vehicle, etanercept (8mg/kg three times a week), the TRPV2 agonist O1821 (20-30mg/Kg/day), or a combination of both. We aimed to compare a transient receptor potential vanilloid 2 (TRPV2) agonist with a TNF inhibitor, and to test the potential of their combination in collagen-induced arthritis (CIA) as a potential future strategy for rheumatoid arthritis (RA).
0 kommentar(er)
